| MeSH term | MeSH ID | Detail |
|---|---|---|
| Asthma | D001249 | 52 associated lipids |
| Kidney Diseases | D007674 | 29 associated lipids |
| Femoral Fractures | D005264 | 7 associated lipids |
| Weight Gain | D015430 | 101 associated lipids |
| Hyperemia | D006940 | 25 associated lipids |
| Cardiovascular Diseases | D002318 | 24 associated lipids |
| Acidosis | D000138 | 13 associated lipids |
| Glioma | D005910 | 112 associated lipids |
| Staphylococcal Infections | D013203 | 15 associated lipids |
| Cell Transformation, Neoplastic | D002471 | 126 associated lipids |
Thromboxane b2
Thromboxane b2 is a lipid of Fatty Acyls (FA) class. Thromboxane b2 is associated with abnormalities such as endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia and Thrombocytosis. The involved functions are known as Platelet Activation, Excretory function, Anabolism, Inflammation and mRNA Expression. Thromboxane b2 often locates in Endothelium, Hepatic and Microsomes, Liver. The associated genes with Thromboxane b2 are PTGS2 gene, prothrombin fragment 2 and CCL14 wt Allele.
Cross Reference
Introduction
To understand associated biological information of Thromboxane b2, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with Thromboxane b2?
Thromboxane b2 is suspected in endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia, Thrombocytosis, Acute Coronary Syndrome and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with Thromboxane b2
PubChem Associated disorders and diseases
What pathways are associated with Thromboxane b2
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with Thromboxane b2?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with Thromboxane b2?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with Thromboxane b2?
There are no associated biomedical information in the current reference collection.
What genes are associated with Thromboxane b2?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with Thromboxane b2?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with Thromboxane b2
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Li CH et al. | [Effect of electroacupuncture at different acupoints on plasma TXB2 and 6-keto-PGF(1alpha), contents in dysmenorrhea rats]. | 2011 | Zhen Ci Yan Jiu | pmid:22073886 |
| Angiolillo DJ et al. | Impact of a fixed-dose combination of naproxen and esomeprazole magnesium on serum thromboxane B2 inhibition by low-dose aspirin over 5 days in healthy adults: a phase I, randomized, double-blind, placebo-controlled, noninferiority trial. | 2011 | Clin Ther | pmid:22078153 |
| Sambu N et al. | Effect of clopidogrel withdrawal on platelet reactivity and vascular inflammatory biomarkers 1 year after drug-eluting stent implantation: results of the prospective, single-centre CESSATION study. | 2011 | Heart | pmid:21795297 |
| Spectre G et al. | Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro- or macrovascular complications. | 2011 | Thromb. Haemost. | pmid:21800009 |
| Hoh CM et al. | Evaluation of effects of low-dose aspirin administration on urinary thromboxane metabolites in healthy dogs. | 2011 | Am. J. Vet. Res. | pmid:21801060 |
| Dalli E et al. | Effects of hawthorn (Crataegus laevigata) on platelet aggregation in healthy volunteers. | 2011 | Thromb. Res. | pmid:21737127 |
| Gao F et al. | Effect of polymorphism and type II diabetes on aspirin resistance in patients with unstable coronary artery disease. | 2011 | Chin. Med. J. | pmid:21740787 |
| Gonçalves LH et al. | Urinary 11-dehydro thromboxane B₂ levels in type 2 diabetic patients before and during aspirin intake. | 2011 | Clin. Chim. Acta | pmid:21510926 |
| Bauer J et al. | Arzanol, a prenylated heterodimeric phloroglucinyl pyrone, inhibits eicosanoid biosynthesis and exhibits anti-inflammatory efficacy in vivo. | 2011 | Biochem. Pharmacol. | pmid:20933508 |
| Oates JC et al. | Selective cyclooxygenase-2 inhibitor suppresses renal thromboxane production but not proliferative lesions in the MRL/lpr murine model of lupus nephritis. | 2011 | Am. J. Med. Sci. | pmid:20924284 |
| Grove EL et al. | Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease. | 2011 | J. Thromb. Haemost. | pmid:20955349 |
| Trostchansky A et al. | Nitroarachidonic acid, a novel peroxidase inhibitor of prostaglandin endoperoxide H synthases 1 and 2. | 2011 | J. Biol. Chem. | pmid:21266582 |
| Trefiletti G et al. | 1-Phenyl-6,7-dihydroxy-isochroman suppresses lipopolysaccharide-induced pro-inflammatory mediator production in human monocytes. | 2011 | Br. J. Nutr. | pmid:21269535 |
| Gremmel T et al. | Comparison of methods to evaluate aspirin-mediated platelet inhibition after percutaneous intervention with stent implantation. | 2011 | Platelets | pmid:21231857 |
| Kuo HL et al. | NP-313, 2-acetylamino-3-chloro-1,4-naphthoquinone, a novel antithrombotic agent with dual inhibition of thromboxane A(2) synthesis and calcium entry. | 2011 | Br. J. Pharmacol. | pmid:21232029 |
| Kleinbongard P et al. | Vasoconstrictor potential of coronary aspirate from patients undergoing stenting of saphenous vein aortocoronary bypass grafts and its pharmacological attenuation. | 2011 | Circ. Res. | pmid:21183739 |
| Kleinbongard P et al. | Acute vasomotor paralysis and potential downstream effects of paclitaxel from stents implanted for saphenous vein aorto-coronary bypass stenosis. | 2011 | Basic Res. Cardiol. | pmid:21472462 |
| Ceprnja M et al. | Oxidative stress markers in patients with post-traumatic stress disorder. | 2011 | Coll Antropol | pmid:22397253 |
| Toliopoulos IK et al. | Inhibition of platelet aggregation and immunomodulation of NK lymphocytes by administration of ascorbic acid. | 2011 | Indian J. Exp. Biol. | pmid:22403863 |
| Lordkipanidzé M et al. | Heterogeneity in platelet cyclooxygenase inhibition by aspirin in coronary artery disease. | 2011 | Int. J. Cardiol. | pmid:20207433 |